Bulk Manufacturer of Controlled Substances Application: Cambrex High Point, Inc., 42902 [2021-16690]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
42902
Federal Register / Vol. 86, No. 148 / Thursday, August 5, 2021 / Notices
Final Judgment are] so inconsonant with
the allegations charged as to fall outside
of the ‘reaches of the public interest.’’’
Microsoft, 56 F.3d at 1461 (quoting W.
Elec. Co., 900 F.2d at 309).
Moreover, the Court’s role under the
APPA is limited to reviewing the
remedy in relationship to the violations
that the United States has alleged in its
complaint, and does not authorize the
Court to ‘‘construct [its] own
hypothetical case and then evaluate the
decree against that case.’’ Microsoft, 56
F.3d at 1459; see also U.S. Airways, 38
F. Supp. 3d at 75 (noting that the court
must simply determine whether there is
a factual foundation for the
government’s decisions such that its
conclusions regarding the proposed
settlements are reasonable); InBev, 2009
U.S. Dist. LEXIS 84787, at *20 (‘‘[T]he
‘public interest’ is not to be measured by
comparing the violations alleged in the
complaint against those the court
believes could have, or even should
have, been alleged’’). Because the
‘‘court’s authority to review the decree
depends entirely on the government’s
exercising its prosecutorial discretion by
bringing a case in the first place,’’ it
follows that ‘‘the court is only
authorized to review the decree itself,’’
and not to ‘‘effectively redraft the
complaint’’ to inquire into other matters
that the United States did not pursue.
Microsoft, 56 F.3d at 1459–60.
In its 2004 amendments to the APPA,
Congress made clear its intent to
preserve the practical benefits of using
judgments proposed by the United
States in antitrust enforcement, Public
Law 108–237 § 221, and added the
unambiguous instruction that ‘‘[n]othing
in this section shall be construed to
require the court to conduct an
evidentiary hearing or to require the
court to permit anyone to intervene.’’ 15
U.S.C. 16(e)(2); see also U.S. Airways,
38 F. Supp. 3d at 76 (indicating that a
court is not required to hold an
evidentiary hearing or to permit
intervenors as part of its review under
the Tunney Act). This language
explicitly wrote into the statute what
Congress intended when it first enacted
the Tunney Act in 1974. As Senator
Tunney explained: ‘‘[t]he court is
nowhere compelled to go to trial or to
engage in extended proceedings which
might have the effect of vitiating the
benefits of prompt and less costly
settlement through the consent decree
process.’’ 119 Cong. Rec. 24,598 (1973)
(statement of Sen. Tunney). ‘‘A court
can make its public interest
determination based on the competitive
impact statement and response to public
comments alone.’’ U.S. Airways, 38 F.
VerDate Sep<11>2014
17:07 Aug 04, 2021
Jkt 253001
Supp. 3d at 76 (citing Enova Corp., 107
F. Supp. 2d at 17).
XVI. Determinative Documents
There are no determinative materials
or documents within the meaning of the
APPA that were considered by the
United States in formulating the
proposed Final Judgment.
Dated: July 28, 2021.
Respectfully submitted,
lllllllllllllllllllll
Brendan Sepulveda (D.C. Bar #1025074),
United States Department of Justice,
Antitrust Division, 450 Fifth Street NW, Suite
7000, Washington, DC 20530, Telephone:
(202) 316–7258, Facsimile: (202) 514–6381,
Email: brendan.sepulveda@usdoj.gov.
Controlled substance
Oxymorphone ..................
Noroxymorphone .............
I
Drug
code
Schedule
9652
9668
II
II
I
The company plans to manufacture
the above listed controlled substances in
bulk for distribution to its customers.
No other activities for these drug codes
are authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–16690 Filed 8–4–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
[FR Doc. 2021–16682 Filed 8–4–21; 8:45 am]
Foreign Claims Settlement
Commission
BILLING CODE 4410–11–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[F.C.S.C. Meeting and Hearing Notice No.
03–21]
Sunshine Act Meeting
[Docket No. DEA–876]
Bulk Manufacturer of Controlled
Substances Application: Cambrex
High Point, Inc.
Drug Enforcement
Administration, Justice.
AGENCY:
ACTION:
Notice of application.
Cambrex High Point, Inc., has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before October 4, 2021. Such persons
may also file a written request for a
hearing on the application on or before
October 4, 2021
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on July 9, 2021, Cambrex
High Point, Inc., 4180 Mendenhall Oaks
Parkway, High Point, North Carolina
27265–8017, applied to be registered as
a bulk manufacturer of the following
basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00127
Fmt 4703
Sfmt 4703
The Foreign Claims Settlement
Commission, pursuant to its regulations
(45 CFR part 503.25) and the
Government in the Sunshine Act (5
U.S.C. 552b), hereby gives notice in
regard to the scheduling of open
meetings as follows:
TIME AND DATE: Tuesday, August 17,
2021, at 10:00 a.m.
PLACE: This meeting will be held by
teleconference. There will be no
physical meeting place.
STATUS: Open. Members of the public
who wish to observe the meeting via
teleconference should contact Patricia
M. Hall, Foreign Claims Settlement
Commission, Tele: (202) 616–6975, two
business days in advance of the
meeting. Individuals will be given callin information upon notice of
attendance to the Commission.
MATTERS TO BE CONSIDERED: 10:00 a.m.—
Issuance of Proposed Decisions under
the Guam World War II Loyalty
Recognition Act, Title XVII, Public Law
114–328.
CONTACT PERSON FOR MORE INFORMATION:
Requests for information, advance
notices of intention to observe an open
meeting, and requests for teleconference
dial-in information may be directed to:
Patricia M. Hall, Foreign Claims
Settlement Commission, 441 G St NW,
Room 6234, Washington, DC 20579.
Telephone: (202) 616–6975.
Jeremy R. LaFrancois,
Chief Administrative Counsel.
[FR Doc. 2021–16859 Filed 8–3–21; 4:15 pm]
BILLING CODE 4410–BA–P
E:\FR\FM\05AUN1.SGM
05AUN1
]]>Agencies
[Federal Register Volume 86, Number 148 (Thursday, August 5, 2021)]
[Notices]
[Page 42902]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-16690]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-876]
Bulk Manufacturer of Controlled Substances Application: Cambrex
High Point, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Cambrex High Point, Inc., has applied to be registered as a
bulk manufacturer of basic class(es) of controlled substance(s). Refer
to Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before October 4, 2021.
Such persons may also file a written request for a hearing on the
application on or before October 4, 2021
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on July 9, 2021, Cambrex High Point, Inc., 4180
Mendenhall Oaks Parkway, High Point, North Carolina 27265-8017, applied
to be registered as a bulk manufacturer of the following basic
class(es) of controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Oxymorphone............................. 9652 II
Noroxymorphone.......................... 9668 II
------------------------------------------------------------------------
The company plans to manufacture the above listed controlled
substances in bulk for distribution to its customers. No other
activities for these drug codes are authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-16690 Filed 8-4-21; 8:45 am]
BILLING CODE P
